- Home
- NAMS vs LIVN Comparison
NAMS vs LIVN Comparison
Compare NAMS & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAMS
- LIVN
- Stock Information
- Founded
- NAMS 2019
- LIVN 1987
- Country
- NAMS Netherlands
- LIVN United Kingdom
- Employees
- NAMS N/A
- LIVN N/A
- Industry
- NAMS Biotechnology: Pharmaceutical Preparations
- LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- NAMS Health Care
- LIVN Health Care
- Exchange
- NAMS Nasdaq
- LIVN Nasdaq
- Market Cap
- NAMS 2.5B
- LIVN 2.1B
- IPO Year
- NAMS N/A
- LIVN 1993
- Fundamental
- Price
- NAMS $19.85
- LIVN $46.13
- Analyst Decision
- NAMS Strong Buy
- LIVN Strong Buy
- Analyst Count
- NAMS 8
- LIVN 7
- Target Price
- NAMS $42.88
- LIVN $59.29
- AVG Volume (30 Days)
- NAMS 1.0M
- LIVN 583.6K
- Earning Date
- NAMS 08-06-2025
- LIVN 07-30-2025
- Dividend Yield
- NAMS N/A
- LIVN N/A
- EPS Growth
- NAMS N/A
- LIVN N/A
- EPS
- NAMS N/A
- LIVN N/A
- Revenue
- NAMS $47,140,000.00
- LIVN $1,275,380,000.00
- Revenue This Year
- NAMS N/A
- LIVN $8.10
- Revenue Next Year
- NAMS N/A
- LIVN $5.76
- P/E Ratio
- NAMS N/A
- LIVN N/A
- Revenue Growth
- NAMS 586.97
- LIVN 7.62
- 52 Week Low
- NAMS $14.06
- LIVN $32.48
- 52 Week High
- NAMS $27.29
- LIVN $57.35
- Technical
- Relative Strength Index (RSI)
- NAMS 52.90
- LIVN 57.28
- Support Level
- NAMS $17.97
- LIVN $44.28
- Resistance Level
- NAMS $19.13
- LIVN $46.30
- Average True Range (ATR)
- NAMS 1.04
- LIVN 1.19
- MACD
- NAMS -0.03
- LIVN -0.16
- Stochastic Oscillator
- NAMS 35.63
- LIVN 67.10
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
About LIVN LivaNova PLC
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.